Hologic $18.3B Take-Private by Blackstone, TPG

In a significant move within the women's health technology sector, Hologic has officially transitioned to private ownership following a substantial $18.3 billion acquisition by investment funds managed by Blackstone and TPG. This transaction marks a new chapter for the global medical technology firm, delisting its common stock from the Nasdaq Stock Market.

The deal, finalized after shareholder approval earlier this year, offers stockholders a combination of immediate cash and a contingent value right. Investors will receive $76 per share in cash, with the potential for an additional $3 per share. This upside is tied to specific revenue targets within Hologic’s Breast Health division for fiscal years 2026 and 2027, incentivizing future performance and innovation.

Adding further weight to the transaction, the acquisition includes minority investments from notable institutional players: a subsidiary of the Abu Dhabi Investment Authority and an affiliate of GIC. This broad investor base underscores confidence in Hologic's strategic direction and growth potential under its new ownership structure.

Coinciding with the completion of the acquisition, José (Joe) E. Almeida has been appointed Chief Executive Officer, effective immediately. Almeida brings a wealth of experience from his previous leadership roles, including serving as Chairman, President, and CEO of Baxter International and leading Covidien before its acquisition by Medtronic. He succeeds Stephen MacMillan, who retired after a long tenure.

The women's health market, a critical segment within the broader MedTech industry, is experiencing sustained growth driven by increasing awareness, diagnostic advancements, and a focus on preventative care. Hologic, with its established portfolio in areas like diagnostics, medical imaging, and surgical products, is well-positioned to capitalize on these trends. The substantial capital infusion from Blackstone and TPG is expected to accelerate innovation and expand the company's global reach.

Under the new private ownership, the focus is anticipated to be on enhancing Hologic's product development pipeline and strengthening its market position. The strategic backing from Blackstone, a firm with extensive experience in healthcare investments, and TPG, known for its long-standing commitment to the sector, provides a robust foundation for achieving these objectives. The leadership transition, with the seasoned Almeida at the helm, signals a commitment to driving operational excellence and advancing the company's mission to improve women's health outcomes worldwide.